Aegis remains bullish on BioLineRx after upbeat BL-8040 news

Aegis' Raghuram Selvaraju is sticking with a Buy rating and a $7 target on shares of BioLineRx (BLRX +13.3%) after today's BL-8040 update.

"It appears to [provide] a dual-layered benefit to patients," Selvaraju says, referencing the company's suggestion that the drug may make cancer cells more susceptible to chemo and may also contribute to cell death.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs